AACR’s “Most Likely To Succeed” Anticancer Technologies
This article was originally published in Pharmaceutical Approvals Monthly
The AACR report celebrates “paradigm-shifting technologies and research areas that could dramatically accelerate advances against all types of cancer.” Some of the advanced technologies that the association thinks are “likely to be successful” include:
You may also be interested in...
Cancer metabolism specialist Agios extends research collaboration with Celgene, picking up an additional $20 million.
Deal with Eisai on epigenetic enzymes is collaborative, whereas in recent tie up with GSK, Epizyme gave up control of development and commercialization of select histone methyltransferases.
An emerging field of oncology drug development offers the potential for eradicating all remaining cancer cells following treatment – and thus preventing recurrence – by targeting the so-called cancer stem cells that are thought to be involved in cancer proliferation, treatment resistance, and metastasis.